Author:
Siegemund M,Pollak N,Seifert O,Wahl K,Hanak K,Vogel A,Nussler A K,Göttsch D,Münkel S,Bantel H,Kontermann R E,Pfizenmaier K
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference43 articles.
1. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ . Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11: 431–449.
2. Holland PM . Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Cancer Lett 2011; e-pub ahead of print 8 January 2011; doi:10.1016/j.canlet.2010.11.001.
3. Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL . Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). ASCO Meeting Abstracts 2010; 28: 8104.
4. Hörnle M, Peters N, Thayaparasingham B, Vörsmann H, Kashkar H, Kulms D . Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 2011; 30: 575–587.
5. Volkmann M, Schiff JH, Hajjar Y, Otto G, Stilgenbauer F, Fiehn W et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med 2001; 79: 594–600.
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献